New vaccine trialMeanwhile, an expert panel convened by ( WHO) has recommended that a single licensed Ebola vaccine be evaluated in a randomised clinical trial for Bundibugyo virus disease. The WHO Technical Advisory Group on candidate vaccine prioritisation for Bundibugyo virus disease recommended Ervebo in a new report issued on Friday. Ervebo is the only licensed vaccine against the main form of Ebola virus disease, also known as Ebola Zaire. WHO convened advisory groups after the Bundibugyo species outbreak in the DRC was declared a Public Health Emergency of International Concern on 16 May. The experts emphasised that a vaccine developed specifically for Bundibugyo virus would remain the preferred option.